Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Other Non-Current Liabilities (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Other Non-Current Liabilities readings, the most recent being $2.6 million for Q4 2022.

  • On a quarterly basis, Other Non-Current Liabilities fell 21.79% to $2.6 million in Q4 2022 year-over-year; TTM through Dec 2022 was $2.6 million, a 21.79% decrease, with the full-year FY2022 number at $2.6 million, down 21.79% from a year prior.
  • Other Non-Current Liabilities hit $2.6 million in Q4 2022 for Cardiol Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $4.3 million in Q2 2022 to a low of $2.6 million in Q4 2022.
  • Median Other Non-Current Liabilities over the past 3 years was $3.4 million (2020), compared with a mean of $3.5 million.
  • The widest YoY moves for Other Non-Current Liabilities: up 4.79% in 2022, down 21.79% in 2022.
  • Cardiol Therapeutics' Other Non-Current Liabilities stood at $3.4 million in 2020, then dropped by 3.16% to $3.3 million in 2021, then fell by 21.79% to $2.6 million in 2022.
  • The last three reported values for Other Non-Current Liabilities were $2.6 million (Q4 2022), $2.7 million (Q3 2022), and $4.3 million (Q2 2022) per Business Quant data.